Molecure 過去の業績

過去基準チェック /06

Molecureの収益は年間平均-44.8%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間12.9% 31.2%割合で減少しています。

主要情報

-44.8%

収益成長率

-42.6%

EPS成長率

Pharmaceuticals 業界の成長	29.4%
収益成長率	-31.2%
株主資本利益率	-38.4%
ネット・マージン	-2,020.9%
前回の決算情報	30 Sep 2024

Recent updates

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

収支内訳

Molecure の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

WSE:MOC 収益、費用、利益 ( )PLN Millions
日付	収益	収益	G+A経費
30 Sep 24	2	-31	26
30 Jun 24	2	-30	27
31 Mar 24	2	-29	27
31 Dec 23	4	-28	28
30 Sep 23	9	-45	45
30 Jun 23	8	-42	41
31 Mar 23	8	-39	38
31 Dec 22	8	-36	35
30 Sep 22	2	-16	16
30 Jun 22	2	-16	15
31 Mar 22	2	-15	14
31 Dec 21	1	-14	12
30 Sep 21	124	63	14
30 Jun 21	124	64	14
31 Mar 21	125	67	12
31 Dec 20	125	68	12
30 Sep 20	2	-3	5
30 Jun 20	2	-3	5
31 Mar 20	2	-4	5
31 Dec 19	2	-4	6
30 Sep 19	2	-5	6
30 Jun 19	2	-5	6
31 Mar 19	1	-5	6
31 Dec 18	1	-4	5
30 Sep 18	1	-4	5
30 Jun 18	2	-4	4
31 Mar 18	2	-2	4
31 Dec 17	1	-2	3
30 Sep 17	1	-3	2
30 Jun 17	1	-3	2
31 Mar 17	1	-3	2
31 Dec 16	1	-2	2
31 Dec 15	1	-1	1

質の高い収益: MOCは現在利益が出ていません。

利益率の向上: MOCは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: MOCは利益が出ておらず、過去 5 年間で損失は年間44.8%の割合で増加しています。

成長の加速: MOCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: MOCは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 8.9% ) と比較することは困難です。

株主資本利益率

高いROE: MOCは現在利益が出ていないため、自己資本利益率 ( -38.4% ) はマイナスです。

Molecure 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06